Tolerability (toxicity, dose intensity and quality adjusted 648 survival (QAS)) of ECMF versus CMF in the national epirubicin adjuvant trial (NEAT) of moderate risk early breast cancer.
BREAST CANCER RESEARCH AND TREATMENT(2002)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要